Completing the Arc: Targeted Inhibition of RET in Medullary Thyroid Cancer

被引：16
|
作者：
Houvras, Yariv [1 ,2 ]
机构：
[1] Weill Cornell Med Coll, New York, NY USA
[2] New York Presbyterian Hosp, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 02期
关键词：
MUTATIONS; CARCINOMAS; VANDETANIB; GENETICS; DISEASE; ZD6474;
D O I：
10.1200/JCO.2011.38.7639
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：200 / 202
页数：3
相关论文
共 50 条
  • [31] Genetics of medullary thyroid cancer: An overview
    Accardo, Giacomo
    Conzo, Giovanni
    Esposito, Daniela
    Gambardella, Claudio
    Mazzella, Marco
    Castaldo, Filomena
    Di Donna, Carlo
    Polistena, Andrea
    Avenia, Nicola
    Colantuoni, Vittorio
    Giugliano, Dario
    Pasquali, Daniela
    INTERNATIONAL JOURNAL OF SURGERY, 2017, 41 : S2 - S6
  • [32] Vandetanib for the Treatment of Medullary Thyroid Cancer
    Chau, Nicole G.
    Haddad, Robert I.
    CLINICAL CANCER RESEARCH, 2013, 19 (03) : 524 - 529
  • [33] Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma
    Silva, A. L.
    Carmo, F.
    Moura, M. M.
    Domingues, R.
    Espadinha, C.
    Leite, V.
    Cavaco, B.
    Bugalho, M. J.
    ENDOCRINE, 2015, 49 (02) : 366 - 372
  • [34] Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma
    Alqahtani, Tariq
    Kumarasamy, Vishnu Muthuraj
    Huczynski, Adam
    Sun, Daekyu
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2020, 56 (01) : 348 - 358
  • [35] Coexistent Familial Nonmultiple Endocrine Neoplasia Medullary Thyroid Carcinoma and Papillary Thyroid Carcinoma Associated With RET Polymorphism
    Gul, Kamile
    Ozdemir, Didem
    Ugras, Serdar
    Inancli, Serap S.
    Ersoy, Reyhan
    Cakir, Bekir
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2010, 340 (01): : 60 - 63
  • [36] Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer
    Bastholt, Lars
    Kreissl, Michael C.
    Fuehrer, Dagmar
    Maia, Ana L.
    Locati, Laura D.
    Maciel, Lea
    Wu, Yi
    Heller, Kevin N.
    Webster, Alan
    Elisei, Rossella
    EUROPEAN THYROID JOURNAL, 2016, 5 (03) : 187 - 194
  • [37] Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer
    Chen, Wenjing
    Dream, Sophie
    Leung, Pui-Yin
    Wu, Pui-Kei
    Wong, Stuart
    Park, Jong-In
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [38] RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation
    Yue, Chia-Herng
    Oner, Muhammet
    Chiu, Chih-Yuan
    Chen, Mei-Chih
    Teng, Chieh-Lin
    Wang, Hsin-Yi
    Hsieh, Jer-Tsong
    Lai, Chih-Ho
    Lin, Ho
    BIOMOLECULES, 2021, 11 (06)
  • [39] Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility
    Toledo, Rodrigo A.
    Hatakana, Roxanne
    Lourenco, Delmar M., Jr.
    Lindsey, Susan C.
    Camacho, Cleber P.
    Almeida, Marcio
    Lima, Jose V., Jr.
    Sekiya, Tomoko
    Garralda, Elena
    Naslavsky, Michel S.
    Yamamoto, Guilherme L.
    Lazar, Monize
    Meirelles, Osorio
    Sobreira, Tiago J. P.
    Lebrao, Maria Lucia
    Duarte, Yeda A. O.
    Blangero, John
    Zatz, Mayana
    Cerutti, Janete M.
    Maciel, Rui M. B.
    Toledo, Sergio P. A.
    ENDOCRINE-RELATED CANCER, 2015, 22 (01) : 65 - 76
  • [40] Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials
    Gil-Bernabe, Sara
    Garcia-DeLaFuente, Lucia
    Garcia-alvarez, Alejandro
    Garcia-Rostan, Ginesa
    Capdevila, Jaume
    Hernando, Jorge
    AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2025,
12345